alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–100 of 113 studies with an author at Radboud University Medical Center (NL) (page 4 of 5) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 113 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Parkinsonism & related disorders 2020-05-21

These data suggest that current treatment of late stage parkinsonism in the community remains insufficiently effective to alleviate disabling symptoms in many patients. 3 key findings →

Participants: 692 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Polygenic risk for white matter hyperintensities is associated with early cerebrovascular events partly through hemodynamic measures in cognitively unimpaired middle-aged and older adults with low cardiovascular risk

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Neurology 2026-01-05

They are often found in middle-aged individuals and are associated with a greater risk of stroke and vascular dementia. 5 key findings →

Participants: 1,072 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Searching for responders to multidomain dementia prevention in late life: A pooled analysis of individual participant data from the MAPT and preDIVA trials

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-01-17

Four hundred eighty-six participants developed dementia during 37,782 person-years of follow-up. 5 key findings →

Participants: 5,205 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Association of Apathy With Incident Dementia: A Multiple Mediation Analysis of Cardiovascular Risk Factors

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International Journal of Geriatric Psychiatry 2025-05-01

Of the association between apathy and dementia (HR 1.49 [95% CI 0.99-2.41]), 27% was mediated by physical inactivity, BMI and diabetes combined. 5 key findings →

Participants: 3,303 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Effect of Multidomain Interventions on Global Cognition, Symptoms of Depression and Apathy - A Pooled Analysis of Two Randomized Controlled Trials

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The journal of prevention of Alzheimer's disease 2022-01-01

Cardiovascular risk factors and lifestyle factors are associated with an increased risk of cognitive decline and dementia in observational studies, and have been targeted by multidomain interventions. 5 key findings →

Participants: 4,162 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD)

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurobiology of disease 2007-06-18

High dietary cholesterol and low dietary docosahexaenoic acid (DHA) intake are risk factors for Alzheimer's disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Clinical chemistry 2007-03-29

Cerebrospinal fluid (CSF) concentrations of amyloid beta(42) (Abeta(42)) peptides and tau proteins may serve as biomarkers for Alzheimer disease (AD). 4 key findings →

Participants: 69 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The American journal of pathology 2005-08-01

Cerebral vascular amyloid beta-protein (Abeta) deposition, also known as cerebral amyloid angiopathy, is a common pathological feature of Alzheimer's disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The perspectives of people with dementia on their future, end of life and on being cared for by others: A qualitative study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Clinical Nursing 2021-01-15

Five overarching themes derived from the interviews were as follows: (a) My life still has value and meaning, (b) I am my own unique individual, (c) I place my trust in other people, (d) The future worries me, and (e) I accept and embrace what life brings. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Downregulation of synapse-associated protein expression and loss of homeostatic microglial control in cerebrospinal fluid of infectious patients with delirium and patients with Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Brain, behavior, and immunity 2020-06-24

Delirium is a complex and multifactorial condition associated with long-term cognitive decline. 4 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Advance care planning and quality of life: A qualitative interview study in people with young-onset dementia and their family caregivers

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Palliative Medicine 2025-03-15

Four themes were found: sense of self, connection to others, acceptance versus resistance in the face of adversity, and orientation toward the future versus focus on the present. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping sex differences in brain and cognition in relation to APOE ε4 and amyloid burden: A longitudinal normative modelling study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2026-01-01

These findings highlight normative modelling's utility in revealing the complex interplay among sex, age, and AD risk in shaping brain structure and cognition in later life. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Neurobiology of disease 2008-12-16

Cholesterol and docosahexenoic acid (DHA) may affect degenerative processes in Alzheimer's Disease (AD) by influencing Abeta metabolism indirectly via the vasculature. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Dementia and geriatric cognitive disorders 2006-09-11

Frontotemporal dementia (FTD) is the second most prevalent dementia after Alzheimer's disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Advance care planning with people living with dementia: ethical considerations of physicians in the United States and the Netherlands

✓ Peer-reviewed alzhub usefulness score 42 out of 100. The Journals of Gerontology Series B 2025-08-21

Interviews with 50 Dutch physicians and 47 American physicians and 3 nurse practitioners generated three themes of ethical considerations: (1) Respecting the autonomy of the person with dementia, (2) Rationality as the basis for decisions and subsequent actions, and (3) Minimizing burden and suffering. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed